|
 Alder Biopharmaceuticals Inc. Completes Series C Financing—Delphi Ventures and TPG Biotech led the $40 million round. Also participating were existing investors Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital. Alder plans to use the financing to advance its lead programs through human clinical trials and to continue to advance its proprietary Mab Xpress yeast antibody production technology. Read the release |
 Fact
On average, it takes 12 months to generate a commercial antibody strain using mammalian cell cultures. Alder’s yeast-based cultures take about 5 weeks.
Fact
The cost of producing mammalian cell cultures is US$300 to $1,000 per gram. Alder’s microbial cultures cost a fraction of this amount.
Fact
Over 75% of antibody manufacturing capacity is held by just four companies. Alder provides an alternative manufacturing process that avoids this bottleneck.
Fact
Abbott Laboratories' Humira® is currently the only FDA-approved antibody that can be self-administered. Alder's antibody discovery technologies will allow any company to identify the unique antibodies that can be self-administered by patients.
Fact
2.5 million people in the United States suffer from rheumatoid arthritis. Half of these patients get no relief whatsoever from current drug therapies.
Fact
Nearly one-third of all cancer patients experience overwhelming fatigue. The condition is left untreated by three in four caregivers due to a lack of effective therapies.
Fact
Approximately 40% of cancer patients are anemic. A growing body of clinical evidence suggests that treating anemia for these millions of cancer sufferers can improve both quality of life and clinical outcomes.
|
||
